PCVX Logo

Vaxcyte, Inc. (PCVX) 

NASDAQ
Market Cap
$10.76B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
825 of 960
Rank in Industry
460 of 550

Largest Insider Buys in Sector

PCVX Stock Price History Chart

PCVX Stock Performance

About Vaxcyte, Inc.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine …

Insider Activity of Vaxcyte, Inc.

Over the last 12 months, insiders at Vaxcyte, Inc. have bought $0 and sold $59.16M worth of Vaxcyte, Inc. stock.

On average, over the past 5 years, insiders at Vaxcyte, Inc. have bought $41.38M and sold $36.17M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 186,000 shares for transaction amount of $2.98M was made by Hopfner Robert Lorne (director) on 2020‑06‑16.

List of Insider Buy and Sell Transactions, Vaxcyte, Inc.

2024-12-18SalePRESIDENT AND CFO
8,000
0.0066%
$88.78$710,249-2.31%
2024-12-09SaleCHIEF EXECUTIVE OFFICER
2,366
0.0019%
$92.25$218,253-2.79%
2024-12-05SaleSVP, GEN COUNSEL & CORP SEC
5,000
0.0041%
$91.49$457,434-0.20%
2024-12-02SaleCHIEF EXECUTIVE OFFICER
15,000
0.0121%
$92.45$1.39M-1.52%
2024-12-02SaleCHIEF OPERATING OFFICER
8,000
0.0064%
$92.49$739,885-1.52%
2024-11-18SalePRESIDENT AND CFO
8,000
0.0064%
$85.81$686,518+0.65%
2024-11-07SaleCHIEF EXECUTIVE OFFICER
2,250
0.0019%
$103.80$233,558-11.34%
2024-11-05SaleSVP, GEN COUNSEL & CORP SEC
5,000
0.0041%
$106.36$531,803-2.57%
2024-11-01SaleCHIEF EXECUTIVE OFFICER
15,000
0.0123%
$106.82$1.6M-14.69%
2024-11-01SaleCHIEF OPERATING OFFICER
8,000
0.0065%
$106.80$854,423-14.69%
2024-10-18SalePRESIDENT AND CFO
42,000
0.0344%
$115.39$4.85M-20.29%
2024-10-07SaleCHIEF EXECUTIVE OFFICER
7,098
0.0057%
$109.21$775,154-11.96%
2024-10-07SaleSVP, GEN COUNSEL & CORP SEC
5,000
0.004%
$109.27$546,353-11.96%
2024-10-01SaleCHIEF EXECUTIVE OFFICER
55,000
0.0463%
$114.25$6.28M-12.55%
2024-10-01SaleCHIEF EXECUTIVE OFFICER
50,712
0.0427%
$114.19$5.79M-12.55%
2024-10-01SaleCHIEF OPERATING OFFICER
8,000
0.0067%
$114.24$913,917-12.55%
2024-10-01SaleSVP, GEN COUNSEL & CORP SEC
5,500
0.0046%
$114.24$628,295-12.55%
2024-09-18SalePRESIDENT AND CFO
8,000
0.0065%
$115.94$927,551-10.06%
2024-09-17Saledirector
6,250
0.0051%
$116.28$726,731-9.58%
2024-09-16SaleCHIEF OPERATING OFFICER
10,000
0.0083%
$115.96$1.16M-7.36%

Insider Historical Profitability

<0.0001%
TPG Group Holdings (SBS) Advisors, Inc.
5074574
4.0715%
$86.3511<0.0001%
EMSTER KURT VONdirector
4168718
3.3447%
$86.3510<0.0001%
Heron Patrick Jdirector
2309554
1.853%
$86.3510<0.0001%
Hopfner Robert Lornedirector
1405418
1.1276%
$86.35121<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Fidelity Investments$1.11B14.9516.26M+14.41%+$139.88M0.07
The Vanguard Group$665.15M8.959.74M+15.2%+$87.77M0.01
BlackRock$649.83M8.749.51M+10.93%+$64.02M0.01
RA Capital Management, L.P.$560.4M7.548.2M+3.96%+$21.35M0.56
Janus Henderson$524.12M7.057.67M+9.92%+$47.3M0.26
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.